세계의 재조합형 세포배양 인슐린 시장 규모, 점유율, 동향 분석 : 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Recombinant Cell Culture Insulin Market Summary

The global recombinant cell culture insulin market size was estimated at USD 233.0 million in 2024 and is projected to reach USD 665.3 million by 2033, growing at a CAGR of 12.5% from 2025 to 2033. The market growth is primarily driven by the increasing adoption of recombinant technologies in biopharmaceutical manufacturing, the rising demand for chemically defined and serum-free media, and the expanding use of insulin as a critical supplement in cell culture applications.

Global Recombinant Cell Culture Insulin Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global recombinant cell culture insulin market based on type, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Stand-alone Powder
• Combined kits & Cocktails
• Liquid Insulin
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutic Protein Originators
• Therapeutic Proteins Biosimilars
• Vaccine Manufacturers
• Regenerative Medicine
• Academic Research Institutes
• Cell Culture Media Manufacturers
• CMOs & CROs
• CDMOs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Types
  • 1.2.2. End use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. Advancements in biotechnology
    • 3.3.1.2. Shift to Defined, Animal-Origin-Free, Serum-Free Media
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High cost and technical complexity
    • 3.3.2.2. Regulation uncertainity
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. Global Recombinant Cell Culture Insulin Market Type, Movement Analysis
• 4.3. Global Recombinant Cell Culture Insulin Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Stand-alone Powder
  • 4.4.1. Global stand-alone powder market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Combined kits & Cocktails
  • 4.5.1. Global combined kits & cocktails market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Liquid Insulin
  • 4.6.1. Global liquid insulin market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. End use Business Analysis

• 5.1. End use Segment Dashboard
• 5.2. Global Recombinant Cell Culture Insulin Market End use, Movement Analysis
• 5.3. Global Recombinant Cell Culture Insulin Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 5.4. Therapeutic Protein Originators
  • 5.4.1. Global Therapeutic Protein Originators market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Therapeutic Proteins Biosimilars
  • 5.5.1. Global therapeutic proteins biosimilars market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Vaccine Manufacturers
  • 5.6.1. Global vaccine manufacturers market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Regenerative Medicine
  • 5.7.1. Global regenerative medicine market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Academic Research Institutes
  • 5.8.1. Global academic research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Cell Culture Media Manufacturers
  • 5.9.1. Global cell culture media manufacturers market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.10. CMOs & CROs
  • 5.10.1. Global CMOs & CROs market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.11. CDMO
  • 5.11.1. Global CDMO market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Recombinant Cell Culture Insulin Market: Regional Estimates and Trend Analysis, by Type, End use, Application, & End-Use

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. North America recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. Competitive Scenario
    • 6.3.2.4. Regulatory Framework
    • 6.3.2.5. U.S. recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Competitive Scenario
    • 6.3.3.4. Regulatory Framework
    • 6.3.3.5. Canada recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Competitive Scenario
    • 6.3.4.4. Regulatory Framework
    • 6.3.4.5. Mexcio recombinant cell culture insulin market, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Regulatory Framework
    • 6.4.2.5. UK recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Regulatory Framework
    • 6.4.3.5. Germany recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Competitive Scenario
    • 6.4.4.4. Regulatory Framework
    • 6.4.4.5. France recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Competitive Scenario
    • 6.4.5.4. Regulatory Framework
    • 6.4.5.5. Italy recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Competitive Scenario
    • 6.4.6.4. Regulatory Framework
    • 6.4.6.5. Spain recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Competitive Scenario
    • 6.4.7.4. Regulatory Framework
    • 6.4.7.5. Denmark recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Competitive Scenario
    • 6.4.8.4. Regulatory Framework
    • 6.4.8.5. Sweden recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Target Disease Prevalence
    • 6.4.9.3. Competitive Scenario
    • 6.4.9.4. Regulatory Framework
    • 6.4.9.5. Norway recombinant cell culture insulin market, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Regulatory Framework
    • 6.5.2.5. Japan recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Regulatory Framework
    • 6.5.3.5. China recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Regulatory Framework
    • 6.5.4.5. India recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Regulatory Framework
    • 6.5.5.5. Australia recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Regulatory Framework
    • 6.5.6.5. Thailand recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Regulatory Framework
    • 6.5.7.5. South Korea recombinant cell culture insulin market, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. Regulatory Framework
    • 6.6.2.5. Brazil recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. Regulatory Framework
    • 6.6.3.5. Argentina recombinant cell culture insulin market, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Regulatory Framework
    • 6.7.2.5. South Africa recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. Regulatory Framework
    • 6.7.3.5. Saudi Arabia recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Target Disease Prevalence
    • 6.7.4.3. Competitive Scenario
    • 6.7.4.4. Regulatory Framework
    • 6.7.4.5. UAE recombinant cell culture insulin market, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Target Disease Prevalence
    • 6.7.5.3. Competitive Scenario
    • 6.7.5.4. Regulatory Framework
    • 6.7.5.5. Kuwait recombinant cell culture insulin market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. Novo Nordisk Pharmatech A/S
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Merck KGaA
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Thermo Fisher Scientific Inc.
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Lonza
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Corning Incorporated
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. GeminiBio LLC.
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Elabascience
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Capricorn Scientific GmbH
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives